{"id":"fec-t-pertuzumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Cardiac dysfunction"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:03:43.894610","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FEC-T is a standard neoadjuvant chemotherapy regimen for breast cancer. Pertuzumab is a HER2 dimerization inhibitor that prevents HER2 from pairing with other HER family receptors, blocking downstream signaling. The combination targets HER2-positive breast cancer through both cytotoxic chemotherapy and targeted HER2 pathway inhibition.","oneSentence":"FEC-T+Pertuzumab combines chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel) with pertuzumab, a HER2-targeted monoclonal antibody that blocks HER2 dimerization to prevent tumor cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:24.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive early-stage breast cancer (neoadjuvant setting)"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT01996267","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2013-12","conditions":"Breast Cancer, HER2 Positive","enrollment":437},{"nctId":"NCT01501487","phase":"PHASE4","title":"MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I","status":"COMPLETED","sponsor":"Agendia","startDate":"2011-10","conditions":"Breast Cancer","enrollment":226},{"nctId":"NCT00976989","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-11","conditions":"Breast Cancer","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fluorouracil; 500 mg/m2; day 1","Epirubicine; 90 mg/m2; day 1","Cyclophosphamide 500 mg/m2; day 1","Trastuzumab; 6 mg/kg (loading dose 8 mg/kg)","Pertuzumab; 420 mg (loading dose 840 mg); day 1"],"phase":"phase_3","status":"active","brandName":"FEC-T+Pertuzumab","genericName":"FEC-T+Pertuzumab","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FEC-T+Pertuzumab combines chemotherapy (5-fluorouracil, epirubicin, cyclophosphamide, and docetaxel) with pertuzumab, a HER2-targeted monoclonal antibody that blocks HER2 dimerization to prevent tumor cell growth. Used for HER2-positive early-stage breast cancer (neoadjuvant setting).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}